PPHM - Peregrine Pharmaceuticals Stock Price, News & Analysis

$4.36 0.13 (3.07 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$4.23
Today's Range$4.23 - $4.36
52-Week Range$1.96 - $5.78
Volume79,793 shs
Average Volume314,250 shs
Market Capitalization$196.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:PPHM
  • CUSIP: N/A
  • Web: www.peregrineinc.com
Debt:
  • Current Ratio: 1.67%
  • Quick Ratio: 1.10%
Sales & Book Value:
  • Annual Sales: $57.63 million
  • Price / Sales: 3.41
  • Book Value: $1.26 per share
  • Price / Book: 3.46
Profitability:
  • Trailing EPS: ($0.58)
  • Net Income: $-28,150,000.00
  • Net Margins: -23.15%
  • Return on Equity: -38.19%
  • Return on Assets: -16.66%
Misc:
  • Employees: 323
  • Outstanding Shares: 45,100,000
 

Frequently Asked Questions for Peregrine Pharmaceuticals (NASDAQ:PPHM)

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

When did Peregrine Pharmaceuticals' stock split? How did Peregrine Pharmaceuticals' stock split work?

Shares of Peregrine Pharmaceuticals reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Peregrine Pharmaceuticals stock prior to the reverse split would have 14 shares after the split.

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) posted its earnings results on Monday, September, 11th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The biopharmaceutical company earned $27.08 million during the quarter, compared to analysts' expectations of $15.22 million. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, December, 11th 2017. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

1 brokers have issued 1-year price targets for Peregrine Pharmaceuticals' stock. Their predictions range from $10.00 to $10.00. On average, they expect Peregrine Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Peregrine Pharmaceuticals.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Carlton M. Johnson Jr., Independent Chairman of the Board (Age 56)
  • Steven W. King, President, Chief Executive Officer, Director (Age 52)
  • Paul J. Lytle, Chief Financial Officer (Age 48)
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary (Age 52)
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property (Age 50)
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs (Age 43)
  • Mark R. Bamforth, Independent Director (Age 52)
  • David H. Pohl, Independent Director (Age 79)
  • Eric S. Swartz, Independent Director (Age 60)
  • Patrick D. Walsh, Independent Director

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%), STAFFORD JOHN S III (7.30%), Bandera Partners LLC (1.23%), Stifel Financial Corp (0.45%) and Eqis Capital Management Inc. (0.32%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who sold Peregrine Pharmaceuticals stock? Who is selling Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Bandera Partners LLC, Brown Advisory Securities LLC, California Public Employees Retirement System, Commonwealth Equity Services Inc, Citadel Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Peregrine Pharmaceuticals.

Who bought Peregrine Pharmaceuticals stock? Who is buying Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Algert Global LLC, OxFORD Asset Management LLP and JPMorgan Chase & Co.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $4.36.

How big of a company is Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals has a market capitalization of $196.62 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Peregrine Pharmaceuticals employs 323 workers across the globe.

How can I contact Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals' mailing address is 14282 Franklin Ave, TUSTIN, CA 92780, United States. The biopharmaceutical company can be reached via phone at +1-714-5086000 or via email at [email protected]


MarketBeat Community Rating for Peregrine Pharmaceuticals (PPHM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Peregrine Pharmaceuticals (NASDAQ:PPHM)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (129.36% upside)

Consensus Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Price Target History for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/29/2017Noble FinancialInitiated CoverageBuy -> Buy$10.00LowView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$3.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$7.00N/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Earnings History by Quarter for Peregrine Pharmaceuticals (NASDAQ PPHM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/11/2017        
9/11/2017Q1 2018($0.12)($0.06)$15.22 million$27.08 millionViewN/AView Earnings Details
7/14/2017Q4 2017($0.07)($0.16)$22.57 million$17.90 millionViewN/AView Earnings Details
3/13/2017Q3 2017($0.21)($0.28)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.21)($0.14)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.28)($0.35)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.21)($0.35)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.49)($0.56)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.63)($0.49)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.56)($0.56)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.56)($0.49)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.56)($0.56)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.49)($0.49)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.42)($0.56)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.49)($0.42)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.42)($0.42)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.35)($0.35)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.35)($0.35)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.42)($0.42)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.49)($0.28)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.63)($0.56)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.77)($0.49)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.91)($0.70)ViewN/AView Earnings Details
3/9/2012($0.91)($0.91)ViewN/AView Earnings Details
12/12/2011($0.91)($1.12)ViewN/AView Earnings Details
9/9/2011($0.98)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Peregrine Pharmaceuticals (NASDAQ PPHM)

Source:
DateHeadline
Peregrine Pharmaceuticals (PPHM) & Catalyst Biosciences (CBIO) Head to Head SurveyPeregrine Pharmaceuticals (PPHM) & Catalyst Biosciences (CBIO) Head to Head Survey
www.americanbankingnews.com - November 20 at 7:54 AM
Peregrine Pharmaceuticals Inc. (PPHM) Raised to Hold at Zacks Investment ResearchPeregrine Pharmaceuticals Inc. (PPHM) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - November 18 at 6:04 AM
Peregrine Announces Date of 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)Peregrine Announces Date of 2017 Annual Meeting of Stockholders - GlobeNewswire (press release)
globenewswire.com - November 14 at 6:55 AM
Peregrine Announces Date of 2017 Annual Meeting of StockholdersPeregrine Announces Date of 2017 Annual Meeting of Stockholders
finance.yahoo.com - November 14 at 6:55 AM
Why Avistas CEO was recruited for Peregrines board - Triangle Business JournalWhy Avista's CEO was recruited for Peregrine's board - Triangle Business Journal
www.bizjournals.com - October 31 at 8:06 AM
Ronin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine PharmaceuticalsRonin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine Pharmaceuticals
finance.yahoo.com - October 31 at 8:06 AM
Peregrine Pharmaceuticals Inc. (PPHM) Director Acquires $225,000.00 in StockPeregrine Pharmaceuticals Inc. (PPHM) Director Acquires $225,000.00 in Stock
www.americanbankingnews.com - October 27 at 8:42 PM
Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine PharmaceuticalsRonin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals
finance.yahoo.com - October 27 at 11:10 AM
Peregrine Pharma (PPHM) Appoints Patrick Walsh to BoardPeregrine Pharma (PPHM) Appoints Patrick Walsh to Board
www.streetinsider.com - October 25 at 9:20 AM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 23, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 23, 2017
finance.yahoo.com - October 25 at 9:20 AM
Peregrine Pharma (PPHM) Appoints Patrick Walsh to Board - StreetInsider.comPeregrine Pharma (PPHM) Appoints Patrick Walsh to Board - StreetInsider.com
www.streetinsider.com - October 24 at 8:43 AM
Peregrine Pharma (PPHM) Appoints Mark Bamforth to Board - StreetInsider.comPeregrine Pharma (PPHM) Appoints Mark Bamforth to Board - StreetInsider.com
www.streetinsider.com - October 19 at 3:33 PM
Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices
finance.yahoo.com - October 19 at 3:33 PM
Contrasting Kadmon Holdings (KDMN) and Peregrine Pharmaceuticals (PPHM)Contrasting Kadmon Holdings (KDMN) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 18 at 8:20 PM
Critical Contrast: Peregrine Pharmaceuticals (PPHM) & Ocera Therapeutics (OCRX)Critical Contrast: Peregrine Pharmaceuticals (PPHM) & Ocera Therapeutics (OCRX)
www.americanbankingnews.com - October 18 at 4:24 PM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 12, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : October 12, 2017
finance.yahoo.com - October 13 at 8:14 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals - PR Newswire (press release)Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals - PR Newswire (press release)
www.prnewswire.com - October 11 at 6:40 AM
Ronin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine PharmaceuticalsRonin Trading and SW Investment Management Announce Additional Nomination to Board of Peregrine Pharmaceuticals
finance.yahoo.com - October 11 at 6:40 AM
Reviewing Peregrine Pharmaceuticals (PPHM) & The CompetitionReviewing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - October 8 at 2:24 PM
Earnings Review and Free Research Report: Peregrine Pharma’s Q1 Top-line Surged 383% Y-o-Y; Beat ProjectionsEarnings Review and Free Research Report: Peregrine Pharma’s Q1 Top-line Surged 383% Y-o-Y; Beat Projections
finance.yahoo.com - October 5 at 5:16 PM
Peregrine Pharmaceuticals Inc. (PPHM) Now Covered by Noble FinancialPeregrine Pharmaceuticals Inc. (PPHM) Now Covered by Noble Financial
www.americanbankingnews.com - September 29 at 6:00 PM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 26, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 7:10 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius ... - GlobeNewswire (press release)Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius ... - GlobeNewswire (press release)
globenewswire.com - September 25 at 5:16 PM
Avid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford FacilityAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford Facility
finance.yahoo.com - September 25 at 12:09 PM
Un-Spinning The Peregrine Pharmaceuticals Spin Zone - Seeking AlphaUn-Spinning The Peregrine Pharmaceuticals Spin Zone - Seeking Alpha
seekingalpha.com - September 22 at 7:01 PM
Comparing Peregrine Pharmaceuticals (PPHM) & The CompetitionComparing Peregrine Pharmaceuticals (PPHM) & The Competition
www.americanbankingnews.com - September 21 at 4:26 PM
Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition - GlobeNewswire (press release)Avid Bioservices to Exhibit at 2017 BioProcess International Conference & Exhibition - GlobeNewswire (press release)
globenewswire.com - September 20 at 7:55 AM
Earnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 ResultsEarnings Review and Free Research Report: Mesoblast Reported Q4 and Full Year FY17 Results
finance.yahoo.com - September 20 at 7:55 AM
Head to Head Review: Peregrine Pharmaceuticals (PPHM) versus Its PeersHead to Head Review: Peregrine Pharmaceuticals (PPHM) versus Its Peers
www.americanbankingnews.com - September 15 at 4:28 PM
Peregrines Well Is Running Dry - Seeking AlphaPeregrine's Well Is Running Dry - Seeking Alpha
seekingalpha.com - September 15 at 7:44 AM
ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 14, 2017ETFs with exposure to Peregrine Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 7:44 AM
Head to Head Contrast: Peregrine Pharmaceuticals (PPHM) & Its CompetitorsHead to Head Contrast: Peregrine Pharmaceuticals (PPHM) & Its Competitors
www.americanbankingnews.com - September 15 at 4:32 AM
Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017Peregrine Pharmaceuticals, Inc. :PPHM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 9:21 AM
Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is QuietStock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet
www.thestreet.com - September 12 at 8:46 AM
Your Weekly Pharma Scoop: Valeants CRL Resolution, Eagle Undervalued, Array Positive ResultsYour Weekly Pharma Scoop: Valeant's CRL Resolution, Eagle Undervalued, Array Positive Results
seekingalpha.com - September 12 at 8:46 AM
Keep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec UplistedKeep Close Watch On ALDX Today, ABBV Just Hit Another High, Fennec Uplisted
www.rttnews.com - September 12 at 8:46 AM
Investor Network: Peregrine Pharmaceuticals, Inc. to Host Earnings CallInvestor Network: Peregrine Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - September 12 at 8:46 AM
Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments
finance.yahoo.com - September 12 at 8:46 AM
Edited Transcript of PPHM earnings conference call or presentation 11-Sep-17 8:30pm GMTEdited Transcript of PPHM earnings conference call or presentation 11-Sep-17 8:30pm GMT
finance.yahoo.com - September 12 at 8:46 AM
Peregrine reports 1Q lossPeregrine reports 1Q loss
finance.yahoo.com - September 12 at 8:46 AM
Peregrine Pharmaceuticals Inc. (PPHM) Posts Quarterly  Earnings Results, Beats Estimates By $0.06 EPSPeregrine Pharmaceuticals Inc. (PPHM) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - September 11 at 8:20 PM
Reviewing Transition Therapeutics (TTHI) & Peregrine Pharmaceuticals (PPHM)Reviewing Transition Therapeutics (TTHI) & Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - September 11 at 12:08 AM
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment ... - GlobeNewswire (press release)Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment ... - GlobeNewswire (press release)
globenewswire.com - September 9 at 7:32 AM
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
finance.yahoo.com - September 8 at 7:15 AM
Peregrine Pharmaceuticals Inc. (PPHM) to Release Quarterly Earnings on MondayPeregrine Pharmaceuticals Inc. (PPHM) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - September 7 at 10:24 AM
Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017
finance.yahoo.com - September 7 at 7:47 AM
Peregrine Pharmaceuticals Inc. (PPHM) Given Average Recommendation of "Hold" by AnalystsPeregrine Pharmaceuticals Inc. (PPHM) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 5 at 6:28 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - August 31 at 8:53 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - August 31 at 8:53 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - August 30 at 8:07 AM

Social Media

Financials

Chart

Peregrine Pharmaceuticals (NASDAQ PPHM) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.